

MASTER'S THESIS

Glutamate receptors in an animal model of Parkinson's disease

Tse, Yiu Chung

Date of Award:
1999

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

Glutamate Receptors in an Animal Model
of Parkinson's Disease

TSE Yiu Chung

A thesis submitted in partial fulfillment of the requirements
for the degree of
Master of Philosophy

October 1999

Hong Kong Baptist University

Abstract

Basal ganglia are a group of subcortical nuclei in the forebrain that are associated with movement of the body. Degeneration of dopaminergic neurons in the basal ganglia, i.e., the neurons in the substantia nigra pars compacta, is the cause of one of the major dysfunction of the basal ganglia, namely Parkinson's disease. In order to develop better treatments for Parkinson's disease, neurotransmitter glutamate and its receptors are implicated as the targets. There is a complicated family of glutamate receptors described so far. The major objectives of the present thesis were to investigate the precise cellular localization of nine glutamate receptor subunits and subtypes (N-methyl-D-aspartate receptors: NMDAR1 and NMDAR2B; α -amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors: GluR1-4; kainate receptors: GluR5/6/7; and metabotropic glutamate receptors: mGluR1 α and mGluR2/3) in the neostriatum and the substantia nigra, the two major areas of the basal ganglia that are known to be affected by the neuropathology of Parkinson's disease. Using an animal model of Parkinson's disease, the 6-hydroxydopamine-lesioned rats, the changes of the glutamate receptors during the course of the motor disorder were then investigated.

In the first part of study, double immunocytochemistry and immunofluorescence was employed to reveal the precise cellular localization of immunoreactivity for glutamate receptor subunits in subpopulations of neurons in the rat substantia nigra. In the substantia nigra pars compacta, around 90 % of the tyrosine hydroxylase-immunoreactive neurons are found to express immunoreactivity for GluR1, GluR2, GluR2/3, NMDAR1 and GluR5/6/7. Only about 60 % of tyrosine hydroxylase-positive neurons were found to express NMDAR2B immunoreactivity. In the substantia nigra pars reticulata, subpopulations of neurons that displayed strong immunoreactivity for parvalbumin and GABA transaminase were found to express immunoreactivity for GluR1, GluR2, GluR2/3, GluR4, NMDAR1, NMDAR2B and GluR5/6/7. These results indicate that the compacta neurons are the major neuronal elements that express most of the ionotropic glutamate receptor subunits in the region. In addition, subpopulations of neurons in the reticulata that express strong immunoreactivity for parvalbumin and GABA transaminase are the major neurons that express most of the ionotropic glutamate receptors.

In the second part of study, immunocytochemistry was employed to localize the precise cellular distribution of immunoreactivity for glutamate receptor subunits and subtypes in the neostriatum. Immunoreactivity for GluR2, GluR2/3, NMDAR1, NMDAR2B and GluR5/6/7, as well as GluR1 was primarily found in neurons that resembled the medium-sized spiny neurons in the neostriatum. Immunoreactivity for GluR1 and GluR4 was primarily found in interneurons. Immunoreactivity for mGluR1 α and mGluR2/3 was mainly found in the neuropilar elements of the neostriatum.

Based on the data obtained above, immunofluorescence was employed to investigate the changes of glutamate receptor immunoreactivity in the substantia nigra of the unilaterally 6-hydroxydopamine-lesioned rats. Lesioned rats were perfuse-fixed at different time periods (2 weeks, 3 months and 1 year of lesion). In the lesioned rats after 2 weeks, 3 months and 1 year of lesion, immunoreactivity for GluR1, GluR2, GluR2/3, NMDAR1, NMDAR2B, GluR5/6/7 was found to be depleted in the substantia nigra pars compacta. In addition, immunoreactivity for GluR1, GluR2, GluR2/3, GluR4, NMDAR1, NMDAR2B, GluR5/6/7, mGluR1 α and mGluR2/3, which was indicated by the immunofluorescence

intensity, was found to be unchanged between the non-lesioned and lesioned substantia nigra pars reticulata. These results confirm that the compacta neurons are the major neuronal populations in the rat substantia nigra that display most of the ionotropic glutamate receptors as immunoreactivity for these glutamate receptors are depleted by the loss of dopaminergic neurons in the compacta. Immunoreactivity for the glutamate receptors in the reticulata may not be modified after the lesion.

In addition, based on the above data, immunofluorescence was also employed to study the changes of glutamate receptor immunoreactivity in the neostriatum after the lesion. Similarly, lesioned rats were perfuse-fixed after the three different time periods (2 weeks, 3 months and 1 year of lesion). Immunoreactivity for GluR1, GluR2, GluR2/3 was found to decrease in terms of immunofluorescence intensity in the neostriatum of 2 week-lesioned rats. Immunoreactivity for GluR1 was also found to decrease in the neostriatum of 3 month-lesioned rats. The present study demonstrates that GluR1, GluR2 and GluR2/3 but not the other glutamate receptors are down regulated in the region during the initial stage of lesion. In later stages of lesion, the receptor immunoreactivity is found to be similar between the lesioned and non-lesioned neostriatum. These results indicate that there is a differential effect of the dopamine denervation to different glutamate receptors in the neostriatum and the changes in receptor immunoreactivity are time dependent.

Last but not least, in order to correlate the aftermath changes of glutamate receptors after the lesion at the cellular level to those at the subcellular level, GluR1 immunoreactivity was revealed in the neostriatum. In the three age groups of lesioned animals, the percentage of GluR1-immunoreactive dendritic spines was found to decrease in the lesioned neostriatum. The present qualitative observations indicate that there may be subcellular changes occur in the neuronal elements that are likely to be spiny neurons after the dopamine denervation.

In summary, results of the present thesis as a whole indicate that there is differential localization of glutamate receptors in the neostriatum and in the substantia nigra. After the 6-hydroxydoapmine-lesioned, there are cellular and subcellular changes of glutamate receptors in the regions that may have implication in future therapeutic applications in treatments of Parkinson's disease.

Table of Contents

Declaration	i
Abstract	ii
Acknowledgements	iv
Table of Contents	v
List of Tables	xviii
List of Figures	xix
List of Abbreviation	xxiv
Chapter 1: General Introduction	1
1.1 The Basal ganglia	1
1.1.1 Nuclei of the basal ganglia	1
1.1.2 Circuitry of the basal ganglia	2
1.1.2.1 Input to the basal ganglia	2
1.1.2.2 Major pathways through the basal ganglia	2
1.1.2.3 Synaptic outputs from the basal ganglia	3
1.1.2.4 Feedback pathway	3
1.1.2.5 Neurotransmitter in major pathways of the basal ganglia	4
1.1.3 The neostriatum	4
1.1.3.1 Internal circuitry of the neostriatum	4
1.1.3.2 Neuronal elements of the neostriatum	5
1.1.3.3 Medium-sized spiny neurons	5
1.1.3.4 Interneurons in the neostriatum	6
1.1.3.4.1 Cholinergic interneurons	6
1.1.3.4.2 <i>Interneurons that contain Somatostatin, neuropeptide Y, or nitric oxide synthetase (NOS)</i>	7
1.1.3.4.3 Interneurons that contain parvalbumin (PV) interneurons	7
1.1.3.5 Microcircuitry of the neostriatum	7
1.1.3.5.1 <i>Nigral feedback pathway</i>	8
1.1.3.5.2 <i>Medium-sized spiny neurons interconnection</i>	8
1.1.3.5.3 <i>Connection between spiny neurons and striatal interneurons</i>	8
1.1.4 The substantia nigra	9
1.1.4.1 Neuronal elements of the substantia nigra	9
1.1.4.2 Output pathways of the substantia nigra	9
1.1.4.3 Synaptic inputs to the substantia nigra	10
1.2 Function of the Basal ganglia	11

1.3 Glutamate and its receptors in the basal ganglia	13
1.3.1 Glutamate receptors	13
1.3.1.1 NMDA receptors	14
1.3.1.2 AMPA receptors	14
1.3.1.3 Kainate receptors	15
1.3.2 Localization of glutamate receptor in the basal ganglia	15
1.3.2.1 Previous finding by <i>in situ</i> hybridization and ligand binding	16
1.3.2.2 Finding glutamate receptors in the basal ganglia by immunocytochemistry	17
1.3.3 Glutamate receptor-mediated excitotoxicity	18
1.4 Parkinson's disease and glutamate receptors	18
1.4.1 Parkinson's disease	18
1.4.2 Treatment of Parkinson's disease	20
1.4.3 Changes of glutamate levels in Parkinson's disease	22
1.4.4 Animal models of Parkinson's disease	22
1.4.5 Glutamate receptors change in Parkinson's disease and 6-OHDA lesioned rat animal model.	23
1.4.5.1 Changes of glutamate receptors in 6-OHDA lesioned rat – animal model of Parkinson's disease	23
1.4.5.1.1 Findings by ligand binding studies	23
1.4.5.1.2 Finding by <i>in situ</i> hybridization	23
1.4.5.1.3 Finding by immunocytochemistry	24
1.4.5.2 Changes of glutamate receptors in postmortem brain of patients with Parkinson's disease	24
1.4.5.2.1 Findings by ligand binding studies	24
1.4.5.2.2 Finding by <i>in situ</i> hybridization	24
1.5 Objectives	25
Figure 1.1 Circuitry of the basal ganglia	28
Figure 1.2 Circuitry of the basal ganglia	29
Chapter 2: Materials and Methods	30
2.1 Overall sequence of procedures:	30
2.2 Animals	31
2.3 6-hydroxydopamine lesion	31
2.3.1 Rat rotation tests	32
2.4 Tissue preparation	32
2.4.1 Perfusion and fixation	32

2.4.2	Vibratome sectioning	32
2.4.3	Pretreatment of sections	33
2.4.3.1	Freeze-thaw procedure	33
2.4.3.2	Sodium borohydride treatment	33
2.5	Immunocytochemistry	33
2.5.1	Avidin-biotin-peroxidase method	33
2.5.2	Immunofluorescence	34
2.5.3	Immunocytochemistry combined with immunofluorescence	35
2.5.4	Double immunofluorescence	35
2.5.5	Control for immunocytochemistry	36
2.5.5.1	Control for avidin-biotin-peroxidase method	36
2.5.5.2	Control for immunofluorescence	36
2.5.5.3	Control for immunocytochemistry combined with immunofluorescence	37
2.5.5.4	Control for double immunofluorescence	37
2.6	Preparation for microscopy	37
2.6.1	Light microscopy	37
2.6.2	Preparation for fluorescence microscopy or laser scan confocal microscopy	38
2.6.3	Preparation for electron microscopy	38
2.6.3.1	Treatment with osmium tetroxide	38
2.6.3.2	Dehydration and embedding in resin	39
2.6.3.3	Ultrathin sections for electron microscopy	39
2.7	Semi-quantitative analysis of intensity of immunofluorescence	39
2.7.1	Fluorescence microscope and laser scan confocal microscope analysis	39
2.7.1.1	Confocal microscope analysis for the 6-OHDA lesion rat substantia nigra	40
2.7.1.2	Confocal microscope analysis for the 6-OHDA lesion rat neostriatum	40
2.7.2	Electron microscopic analysis	41
Chapter 3: Localization and characterization of glutamate receptor subunits/subtypes in the rat substantia nigra		42
3.1	Introduction	42
3.1.1	Objectives	44

3.2 Materials and Methods	45
3.2.1 Animals	45
3.2.2 Tissue preparation	45
3.2.2.1 Perfusion and fixation	45
3.2.2.2 Vibratome sectioning	45
3.2.3 Immunocytochemistry combined with immunofluorescence	46
3.2.4 Double immunofluorescence	47
3.2.5 Control for immunocytochemistry	48
3.2.5.1 Control for immunocytochemistry combined with immunofluorescence	48
3.2.5.2 Control for double immunofluorescence	48
3.2.6 Preparation for light and fluorescence microscopy and laser scan confocal microscopy	49
3.3 Results	49
3.3.1 Glutamate receptors in the dopaminergic neurons of the substantia nigra	49
3.3.1.1 GluR1 immunoreactivity	49
3.3.1.2 GluR2 immunoreactivity	50
3.3.1.3 GluR2/3 immunoreactivity	50
3.3.1.4 GluR4 immunoreactivity	51
3.3.1.5 NMDAR1 immunoreactivity	51
3.3.1.6 NMDAR2B immunoreactivity	52
3.3.1.7 GluR5/6/7 immunoreactivity	52
3.3.2 Glutamate receptors in the GABAergic neurons of the substantia nigra	53
3.3.2.1 Double labeling of TH and PV	53
3.3.2.2 Double labeling of GluR1 and PV	53
3.3.2.3 Double labeling of GluR2/3 and PV	54
3.3.2.4 Double labeling of GluR4 and PV	54
3.3.2.5 Double labeling of NMDAR1 and PV	54
3.3.2.6 Double labeling of NMDAR2B and PV	55
3.3.2.7 Double labeling of TH and GABA _T	55
3.3.2.8 Double labeling of GluR1 and GABA _T	56
3.3.2.9 Double labeling of GluR2/3 and GABA _T	56
3.3.2.10 Double labeling of GluR4 and GABA _T	57
3.3.2.11 Double labeling of NMDAR1 and GABA _T	57
3.3.2.12 Double labeling of NMDAR2B and GABA _T	57

3.3.3 AMPA type glutamate receptor subunits in the neurons of the substantia nigra pars reticulata	58
3.3.3.1 Double labeling of GluR1 and GluR2	58
3.3.3.2 Double labeling of GluR2 and GluR4	58
3.4 Discussion	58
3.4.1 Stiochiometry of ionotropic glutamate receptors in dopaminergic neurons of the compacta	59
3.4.1.1 AMPA channels	59
3.4.1.2 NMDA channels	59
3.4.1.3 Kainate channel	61
3.4.2 Stiochiometry of ionotropic glutamate receptors in dopaminergic neurons of the compacta	62
3.4.2.1 AMPA channels	62
3.4.2.2 NMDA channels	63
3.4.3 Expression of ionotropic receptors in subpopulations of reticulata neurons and implications of neurological diseases	64
3.6 Conclusion	66
Figure 3.1 Light and fluorescent micrographs of the rat substantia nigra double immunostained to reveal tyrosine hydroxylase (TH) immunoreactivity together with immunoreactivity for AMPA-type glutamate receptor subunits GluR1 and GluR2	67
Figure 3.2 Light and fluorescent micrographs of the rat substantia nigra double immunostained to reveal tyrosine hydroxylase (TH) immunoreactivity together with immunoreactivity for GluR2/3 and GluR4 receptors	69
Figure 3.3 Light and fluorescent micrographs of the rat substantia nigra double immunostained to reveal tyrosine hydroxylase (TH) immunoreactivity together with immunoreactivity for NMDAR1 and NMDAR2B receptor subunits	71
Figure 3.4 Light and fluorescent micrographs of the rat substantia nigra double immunostained to reveal tyrosine hydroxylase (TH) immunoreactivity together with immunoreactivity for GluR5/6/7	73
Figure 3.5 Color micrographs of the rat substantia nigra double immunostained to reveal immunoreactivity for tyrosine hydroxylase (TH) and parvalbumin (PV), and immuoreactivity for GluR1 and PV	75
Figure 3.6 Color fluorescent micrographs of the rat substantia nigra double labeled to reveal immunoreactivity for PV immunoreactivity together with immunoreactivity for GluR2/3 and GluR4 receptor subunits	77

Figure 3.7	Color fluorescent micrographs of the rat substantia nigra double immunostained to reveal immunoreactivity for PV together with immunoreactivity for NMDAR1 and NMDAR2B receptors	79
Figure 3.8	Color fluorescent micrographs of the rat substantia nigra double immunostained to reveal immunoreactivity for TH and GABA _T and immuoreactivity for GluR1 and GABA _T	81
Figure 3.9	Color fluorescent micrographs of the rat substantia nigra double immunostained to reveal immunoreactivity for GABA _T together with immunoreactivity for GluR2/3, GluR4, NMDAR1 and NMDAR2B	83
Figure 3.10	Color fluorescent micrographs of the rat substantia nigra pars reticulata double immunostained to reveal immunoreactivity for GluR1 and GluR2 and immunoreactivity for GluR4 and GluR2	85

Chapter 4: Localization of glutamate receptors in the neostriatum

4.1 Introduction	87
4.1.1 Objectives	89
4.2 Materials and Methods	90
4.2.1 Animals	90
4.2.2 Tissue preparation	90
4.2.2.1 Perfusion and fixation	90
4.2.2.2 Vibratome sectioning	90
4.2.3 Immunocytochemistry (avidin-biotin-peroxidase method)	91
4.2.4 Control for immunocytochemistry (avidin-biotin-peroxidase method)	91
4.2.5 Preparation for light microscopy	92
4.3 Results	92
4.3.1 GluR1 immunoreactivity	92
4.3.2 GluR2 immunoreactivity	92
4.3.3 GluR2/3 immunoreactivity	93
4.3.4 GluR4 immunoreactivity	93
4.3.5 NMDAR1 immunoreactivity	94
4.3.6 NMDAR2B immunoreactivity	94
4.3.7 GluR5/6/7 immunoreactivity	95
4.3.8 mGluR1 α immunoreactivity	95
4.3.9 mGluR2/3 immunoreactivity	95

4.4 Discussion	95
4.4.1 Differential localization of glutamate receptor subunits/ subtypes in distinct neuronal elements of the neostriatum	96
4.4.2 Functional implications of glutamate receptor localization in the microcircuitry of the neostriatum	97
4.4.2.1 AMPA-type receptor	97
4.4.2.2 NMDA-type receptor	98
4.4.2.3 Kainate receptor	99
4.4.2.4 Metabotropic glutamate receptors	100
4.5 Conclusion	100
Figure 4.1 Light micrographs of the rat neostriatum to reveal immunoreactivity for AMPA-type receptor subunits.	101
Figure 4.2 Light micrographs show immunoreactivity for subunits/subtypes of NMDA-type, kainate and metabotropic receptor in the neostriatum	103
 Chapter 5: Changes of immunoreactivity for glutamate receptors in the substantia nigra in 6-hydroxydopamine- lesioned rats	 105
5.1 Introduction	105
5.1.1 Objectives	107
5.2 Materials and methods	108
5.2.1 Animals	108
5.2.2 6-hydroxydopamine lesion	108
5.2.2.1 Rat rotation tests	108
5.2.3 Tissue preparation	109
5.2.3.1 Perfusion and fixation	109
5.2.3.2 Vibratome sectioning	109
5.2.4 Immunofluorescence	109
5.2.5 Control for immunofluorescence	110
5.2.6 Preparation for laser scan confocal microscope	110
5.2.7 Semi-quantitative analysis of intensity of immunofluorescence analysis	110
5.3 Results	111
5.3.1 Changes of TH immunoreactivity in lesioned rats	111
5.3.2 Changes of glutamate receptors in rats after 2 weeks of lesion	111

5.3.2.1 AMPA type receptor	111
5.3.2.2 NMDA type receptor	113
5.3.2.3 Kainate receptor	114
5.3.2.4 Metabotropic type receptor	114
5.3.3 Changes of glutamate receptors in rats after 3 months of lesion	115
5.3.3.1 AMPA type receptor	115
5.3.3.2 NMDA type receptor	116
5.3.3.3 Kainate receptor	116
5.3.3.4 Metabotropic type receptor	117
5.3.4 Changes of glutamate receptors in rats after 1 year of lesion	117
5.3.4.1 AMPA type receptor	117
5.3.4.2 NMDA receptor	118
5.3.4.3 Kainate receptor	118
5.3.4.4 Metabotropic type receptor	119
5.4 Discussion	119
5.4.1 Effects on glutamate receptors in the SNc after 6-OHDA lesion	120
5.4.2 Effects on glutamate receptors in the SNr after 6-OHDA lesion	121
5.4.3 Functional implications	122
5.5 Conclusion	122
Table 5.1 Relative intensity of glutamate receptor subunits/subtypes in the SNr of 2 weeks 6-OHDA-lesioned rats	123
Figure 5.1 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for tyrosine hydroxylase (TH) and GluR1	124
Figure 5.2 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR2	126
Figure 5.3 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR2/3	128
Figure 5.4 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR4	130
Figure 5.5 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for NMDAR1	132
Figure 5.6 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for NMDAR2B	134
Figure 5.7 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR5/6/7	136

Figure 5.8	Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for mGluR1 α and mGluR2/3	138
Table 5.2	Relative intensity of glutamate receptor subunits/subtypes in the SNr of 3 months 6-OHDA-lesioned rats	140
Figure 5.9	Fluorescent micrographs of the 3 months 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR1 and GluR2	141
Figure 5.10	Fluorescent micrographs of the 3 months 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR2/3 and GluR4	143
Figure 5.11	Fluorescent micrographs of the 3 month 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for NMDAR1 and NMDAR2B	145
Figure 5.12	Fluorescent micrographs of the 3 months 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR5/6/7	147
Figure 5.13	Fluorescent micrographs of the 3 month 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for mGluR1 α and mGluR2/3	149
Table 5.3	Relative intensity of glutamate receptor subunits/subtypes in the SNr of 1 year 6-OHDA-lesioned rats	151
Figure 5.14	Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR1 and GluR2	152
Figure 5.15	Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR2/3 and GluR4	154
Figure 5.16	Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for NMDAR1 and NMDAR2B	156
Figure 5.17	Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for GluR5/6/7	158
Figure 5.18	Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat substantia nigra (SN) to reveal immunoreactivity for mGluR1 α and mGluR2/3	160

Chapter 6: Changes of immunoreactivity for glutamate receptors in the neostriatum in 6-hydroxydopamine-lesioned rats

6.1 Introduction	162
6.1.1 Objectives	164
6.2 Materials and methods	165
6.2.1 Animals	165

6.2.2 6-hydroxydopamine lesion	165
6.2.2.1 Rat rotation tests	166
6.2.3 Tissue preparation	166
6.2.3.1 Perfusion and fixation	166
6.2.3.2 Vibratome sectioning	166
6.2.4 Immunofluorescence	167
6.2.5 Control for immunofluorescence	167
6.2.6 Preparation for laser scan confocal microscopy	167
6.2.7 Laser scan confocal microscope analysis	168
6.3 Results	168
6.3.1 Changes of TH immunoreactivity in lesioned rats	168
6.3.2 Changes of glutamate receptors in rats after 2 weeks of lesion	169
6.3.2.1 AMPA receptor	169
6.3.2.2 NMDA receptor	170
6.3.2.3 Kainate receptor	171
6.3.2.4 Metabotropic type receptor	171
6.3.3 Changes of glutamate receptors in rats after 3 months of lesion	172
6.3.3.1 AMPA receptor	172
6.3.3.2 NMDA receptor	173
6.3.3.3 Kainate receptor	173
6.3.3.4 Metabotropic type receptor	174
6.3.4 Changes of glutamate receptors in rats after 1 year of lesion	174
6.3.4.1 AMPA receptor	174
6.3.4.2 NMDA receptor	175
6.3.4.3 Kainate receptor	175
6.3.3.4 Metabotropic type receptor	175
6.4 Discussion	176
6.4.1 Changes of glutamate receptors – comparison with previous reports	176
6.4.2 Changes of receptor immunoreactivity in the striatal neuronal elements	178
6.4.3 Changes of AMPA receptor during the course of lesion	179
6.4.4 Change of metabotropic glutamate receptors in the Str	180
6.5 Conclusion	181

Table 6.1 Relative intensity of glutamate receptor subunits/subtypes in the Str of 2 weeks 6-OHDA-lesioned rats	182
Figure 6.1 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for tyrosine hydroxylase (TH) and GluR1	183
Figure 6.2 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR2	185
Figure 6.3 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR2/3	187
Figure 6.4 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR4	189
Figure 6.5 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for NMDAR1	191
Figure 6.6 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for NMDAR2B	193
Figure 6.7 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR5/6/7	195
Figure 6.8 Fluorescent micrographs of the 2 weeks 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for mGluR1 α and mGluR2/3	197
Table 6.2 Relative intensity of glutamate receptor subunits/subtypes in the Str of 3 months 6-OHDA-lesioned rats	199
Figure 6.9 Fluorescent micrographs of the 3 months 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR1 and GluR2	200
Figure 6.10 Fluorescent micrographs of the 3 months 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR2/3 and GluR4	202
Figure 6.11 Fluorescent micrographs of the 3 months 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for NMDAR1 and NMDAR2B	204
Figure 6.12 Fluorescent micrographs of the 3 months 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR5/6/7	206
Figure 6.13 Fluorescent micrographs of the 3 months 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for mGluR1 α and mGluR2/3	208
Table 6.3 Relative intensity of glutamate receptor subunits/subtypes in the Str of 1 year 6-OHDA-lesioned rats	210
Figure 6.14 Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR1 and GluR2	211
Figure 6.15 Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR2/3 and GluR4	213
Figure 6.16 Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for NMDAR1 and NMDAR2B	215

Figure 6.17	Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for GluR5/6/7	217
Figure 6.18	Fluorescent micrographs of the 1 year 6-OHDA-lesioned rat neostriatum (Str) to reveal immunoreactivity for mGluR1 α and mGluR2/3	219

Chapter 7: Electron microscopic analysis of GluR1 immunoreactivity in the neostriatum of 6-hydroxydopamine-lesioned rat

7.1 Introduction		221
7.1.1 Objective		222
7.2 Materials and methods		222
7.2.1 Animals		222
7.2.2 Six-hydroxydopamine lesion		223
7.2.2.1 Rat rotation tests		223
7.2.3 Tissue preparation		223
7.2.3.1 Perfusion and fixation		223
7.2.3.2 Vibratome sectioning		224
7.2.4 Pretreatment of sections		224
7.2.4.1 Freeze-thaw procedure		224
7.2.4.2 Sodium borohydride treatment		224
7.2.5 Immunocytochemistry (avidin-biotin-peroxidase method)		225
7.2.6 Control for avidin-biotin-peroxidase method		225
7.2.7 Preparation for electron microscope		226
7.2.7.1 Treatment with osmium tetroxide		226
7.2.7.2 Dehydration and embedding in resin		226
7.2.7.3 Ultrathin sections for electron microscope		226
7.2.8 Electron microscope analysis		227
7.3 Results		227
7.3.1 Electron microscopic analysis		227
7.3.1.1 Immunoreactivity for GluR1 in non-lesioned Str		227
7.3.2 Immunoreactivity for GluR1 in lesioned Str		228
7.3.2.1 Analysis of GluR1-immunoreactive structures		228
7.4 Discussion		228
7.4.1 Subcellular distribution of GluR1-immunoreactive profiles in the lesioned Str		229

7.4.2 Subcellular events of 6-OHDA lesion	229
Table 7.1 Table to show the percentage of different GluR1-immunoreactive profiles in the Str of non-lesioned and lesioned sides in 2 weeks, 3 months and 1 year lesioned 6-OHDA lesioned rats	231
Figure 7.1 Electron micrographs of the non-lesioned side neostriatum (Str) of 6-OHDA-lesioned rat immunostained to reveal immunoreactivity for GluR1 subunit of AMPA receptor	232
Figure 7.2 Electron micrographs of the lesioned side neostriatum (Str) of 6-OHDA-lesioned rat immunostained to reveal immunoreactivity for GluR1 subunit of AMPA receptor	234
Chapter 8:Glutamate receptors in 6-OHDA lesioned rats: localization and functional implications	236
8.1 Glutamate receptors: differential localization of subunits determines functions	236
8.2 Changes of glutamate receptors in the 6-OHDA lesion model and implications in clinical applications	237
8.3 Further questions raised by the findings of the present thesis and further studies	238
Reference list	240
Appendix I	249
Appendix II	250
Appendix III	251
List of Publications	253
Curriculum Vitae	254